ETFs Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
7.890 ^USD	-0.25%		-11.45%	-10.54%

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT

ETFs positioned on Vanda Pharmaceuticals Inc.

Name	Varia. Jan 1.	Weight	AuM
HARTFORD MULTIFACTOR SMALL CAP ETF - USD	+3.91%	0.34%	30 M€
ROYCE QUANT SMALL-CAP QUALITY VALUE ETF - USD	+2.91%	0.22%	20 M€
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	+2.90%	0.01%	7 M€
VANGUARD US TOTAL MARKET SHARES INDEX ETF	-4.99%	0%	293,477 M€
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	+1.77%	0%	35 M€

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

533

Sector

Biotechnology & Medical Research

More about the company